Cartesian Therapeutics (RNAC) Common Equity (2015 - 2026)

Cartesian Therapeutics (RNAC) has 12 years of Common Equity data on file, last reported at -$148.1 million in Q1 2026.

• On a quarterly basis, Common Equity fell 579.78% year-over-year to -$148.1 million in Q1 2026; TTM through Mar 2026 was -$148.1 million, a 579.78% decrease from a year earlier, with the FY2025 full-year figure at -$126.2 million, down 1755.92% from the prior year.
• Common Equity for Q1 2026 stood at -$148.1 million, down from -$126.2 million in the prior quarter.
• Over the last five years, Common Equity for RNAC reached as high as $93.8 million in Q4 2022 and fell as low as -$440.2 million in Q4 2023.
• Historically, Common Equity has averaged -$27.9 million across 5 years, with a median of -$2.5 million in 2025.
• Across the five-year window, Common Equity jumped 2222.36% in 2022 and plunged 4866.49% in 2025, its largest moves.
• Year by year, Common Equity stood at $93.8 million in 2022, then tumbled by 569.14% to -$440.2 million in 2023, then jumped by 98.45% to -$6.8 million in 2024, then slumped by 1755.92% to -$126.2 million in 2025, then decreased by 17.33% to -$148.1 million in 2026.
• Per Business Quant data, the three most recent Common Equity figures were -$148.1 million in Q1 2026, -$126.2 million in Q4 2025, and -$35.8 million in Q3 2025.